| Literature DB >> 32601682 |
James M Dittman1, Wayne Tse2, Michael F Amendola2.
Abstract
INTRODUCTION: In response to the Coronavirus 2019 (COVID-19) pandemic, vascular surgeons in the Veteran Affairs Health Care System have been undertaking only essential cases, such as advanced critical limb ischemia. Surgical risk assessment in these patients is often complex, considers all factors known to impact short- and long-term outcomes, and the additional risk that COVID-19 infection could convey in this patient population is unknown. The European Centre for Disease Prevention and Control (ECDC) published risk factors (ECDC-RF) implicated in increased COVID-19 hospitalization and case-fatality which have been further evidenced by initial reports from the United States Centers for Disease Control and Prevention. CDC reports additionally indicate that African American (AA) patients have incurred disparate infection outcomes in the United States. We set forth to survey the Veterans Affairs Surgical Quality Improvement Program (VASQIP) database over a nearly 20 year span to inform ongoing risk assessment with an estimation of the prevalence of ECDC-RF in our veteran critical limb ischemia population and investigate whether an increased COVID-19 comorbidity burden exists for AA veterans presenting for major non-traumatic amputation.Entities:
Year: 2020 PMID: 32601682 PMCID: PMC7337786 DOI: 10.1093/milmed/usaa180
Source DB: PubMed Journal: Mil Med ISSN: 0026-4075 Impact factor: 1.437
Prevalence of COVID-19 Progression Risk Factors in Presenting Veteran Major Lower Extremity Amputation Patients
| BKAs 1999–2018 n = 28,768 | AKAs 1999–2018 n = 21,315 | ||||
|---|---|---|---|---|---|
| COVID-19 progression risk factors as recorded in preoperative history | Patient count | Not reported | Patient count | Not reported |
|
| Male | 28,470 (99%) | 0 | 21,050 (98.8%) | 0 | .0329 |
| Age 60+ | 20,115 (7.0%) | 0 |
| 0 | <.0001 |
| Smoker (current or past) | 12,630 (44.0%) | 66 |
| 93 | <.0001 |
| Presence of any COVID-19 comorbidity |
| 0 | 17,558 (82.4%) | 0 | <.0001 |
| Diabetes |
| 73 | 10,817 (51.0%) | 89 | <.0001 |
| Cardiovascular disease | 4,423 (15.4%) | 1 | 3,385 (15.9%) | 1 | .1257 |
| Hypertension |
| 606 | 11,164 (52.4%) | 834 | <.0001 |
| COPD | 4,802 (16.7%) | 1 |
| 2 | <.0001 |
| Cancer | 312 (1.1%) | 0 |
| 3 | <.0001 |
A comparison of COVID-19 risk factor prevalence between all presenting non-traumatic AKA and BKA recorded in the VASQIP database from 1999 to 2018.
Bold text indicates a significant difference and the respective highest value between cohorts.
Comparison of COVID-19 Progression Risk Factors In Presenting Veteran BKA Patients by Race
| COVID-19 risk factor | AA BKA n = 7,237 | Non-AA BKA n = 21,531 |
|
|---|---|---|---|
| Hypertension |
| 12,113 (56.2%) |
|
| Diabetes | 5,203 (71.9%) | 15,295 (71.0%) | .1679 |
| COPD | 854 (11.8%) |
|
|
| Cancer | 81 (1.1%) | 231 (1.1%) | .7918 |
| Cardiovascular disease | 1,055 (14.6%) |
|
|
| Presence of any comorbidity |
| 19,047 (88.5%) |
|
All patients presenting for non-traumatic BKA recorded in the VASQIP database from 1999 to 2018 were divided into two groups—AA versus all other races (non-AA). The prevalence of published risk factors for COVID-19 progression as recorded in preoperative history were compared between these two groups to investigate whether AA patients in the BKA population may face disparate risks to COVID-19 based on comorbidity burden alone.
Bold text indicates a significant difference and the respective highest value between cohorts.
Comparison of COVID-19 Progression Risk Factors In Presenting Veteran AKA Patients by Race
| COVID-19 risk factor | AA AKA n = 5,547 | non-AA AKA n = 15,768 |
|
|---|---|---|---|
| Hypertension |
| 8,188 (51.9%) |
|
| Diabetes | 2,716 (49.0%) | 8,101 (51.4%) | .1302 |
| COPD | 947 (17.1%) |
|
|
| Cancer | 104 (1.9%) | 276 (1.8%) | 0.5866 |
| Cardiovascular disease | 847 (15.3%) | 2,538 (16.1%) | 0.1536 |
| Presence of any comorbidity | 4,470 (80.6%) |
|
|
All patients presenting for non-traumatic AKA recorded in the VASQIP database from 1999 to 2018 were divided into two groups—AA versus all other races (non-AA). The prevalence of published risk factors for COVID-19 progression as recorded in preoperative history were compared between these two groups to investigate whether AA patients in the BKA population may face disparate risks to COVID-19 based on comorbidity burden alone.
Bold text indicates a significant difference and the respective highest value between cohorts.